Application | Comment | Organism |
---|---|---|
molecular biology | results demonstrate that the activation peptide is not required for TAFIa activity or for stabilization of the enzyme, but solely for stabilization of the zymogen | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
R302Q | mutant aggregates similarly to wild-type protein | Homo sapiens |
T325I/T329I/H333Y/H335Q | inactive mutant has a 70fold increased half-life and a 3fold to 5fold increased antifibrinolytic function as compared to wild-type, mutant aggregates into large, insoluble complexes that can be removed by centrifugation | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Posttranslational Modification | Comment | Organism |
---|---|---|
proteolytic modification | proteolytic enzymes activate TAFI into TAFIa, by cleaving off the N-terminal activation peptide (amino acids 1-92), from the enzyme moiety. TAFIa is active both before and after removal of the activation peptide, and the half-life of TAFIa is identical in the two preparations | Homo sapiens |
Purification (Comment) | Organism |
---|---|
using a Nik-9H10-Sepharose column, coupled with the antibody Nig9H10 whose epitope is located on the activation peptide of TAFI | Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
hippuryl-L-arginine + H2O | - |
Homo sapiens | hippuric acid + L-arginine | - |
? |
Synonyms | Comment | Organism |
---|---|---|
TAFIa | - |
Homo sapiens |
thrombin-activatable fibrinolysis inhibitor | - |
Homo sapiens |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Homo sapiens |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
8 | - |
assay at | Homo sapiens |